Novartis DEB025 proven as effective interferon-free therapy in hepatitis C
DEB025 belongs to a new class of drugs called cyclophilin inhibitors and offers an effective treatment option across HCV genotypes, with a high barrier to resistance. The 12-week
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.